Assignee
EPIVAX INC
US·19 granted patents·18 pending applications·98 citations·filing 2008–2024
Top patents by PatentIndex Score
37 records- 0198US7884184B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2008·Granted Feb 8, 2011·72 cites·13 claims
- 0290US10980867B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2019·Granted Apr 20, 2021·3 cites·10 claims
- 0390US10925942B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2019·Granted Feb 23, 2021·3 cites·10 claims
- 0489US10925939B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Feb 23, 2021·3 cites·10 claims
- 0589US10925941B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Feb 23, 2021·3 cites·10 claims
- 0689US10925940B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Feb 23, 2021·3 cites·10 claims
- 0789US10751397B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Aug 25, 2020·3 cites·10 claims
- 0888US10213496B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2015·Granted Feb 26, 2019·3 cites·10 claims
- 0983US11045528B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1083US11045530B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1183US11045532B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1283US11045529B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1383US11045531B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2018·Granted Jun 29, 2021·1 cites·19 claims
- 1483US2022211827A1Regulatory t cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2022·Application pending·0 cites
- 1580US12016909B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2021·Granted Jun 25, 2024·0 cites·19 claims
- 1680US11844826B2Regulatory T cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2021·Granted Dec 19, 2023·0 cites·10 claims
- 1776US12275956B2Regulatory T cell epitopesEPIVAX INC·Filed 2022·Granted Apr 15, 2025·0 cites·16 claims
- 1875US2024316101A1Regulatory t cell epitopesEPIVAX INC·Filed 2024·Application pending·0 cites
- 1974US2019351036A1Regulatory t cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2019·Application pending·0 cites
- 2071US11911414B2Regulatory T cell epitopesEPIVAX INC·Filed 2021·Granted Feb 27, 2024·0 cites·9 claims
- 2170US2023279072A1Regulatory t cell epitopesEPIVAX INC·Filed 2022·Application pending·0 cites
- 2269US2023190915A1T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19EPIVAX INC·Filed 2021·Application pending·0 cites
- 2367US2023242591A1Regulatory t cell epitopes and detolerized sars-cov-2 antigensEPIVAX INC·Filed 2021·Application pending·0 cites
- 2467US2023151061A1T cell epitope clusters and related compositions useful in the prevention, diagnosis, and treatment of covid-19EPIVAX INC·Filed 2021·Application pending·0 cites
- 2562US2021300985A1Regulatory t cell epitopesEPIVAX INC·Filed 2021·Application pending·0 cites
- 2661US2011182921A1Regulatory t cell epitopes, compositions and uses thereofEPIVAX INC·Filed 2010·Application pending·0 cites
- 2758US2018161419A1Methods for improving the efficacy of vaccine antigensEPIVAX INC·Filed 2017·Application pending·0 cites
- 2857US2024173377A1Retro - inverso regulatory t cell epitopesEPIVAX INC·Filed 2021·Application pending·0 cites
- 2957US2023321237A1Regulatory t cell epitopesEPIVAX INC·Filed 2021·Application pending·0 cites
- 3056US11441122B2Regulatory T cell epitopesEPIVAX INC·Filed 2018·Granted Sep 13, 2022·0 cites·9 claims
- 3156US2019105386A1Methods for improving the efficacy of vaccine antigensEPIVAX INC·Filed 2018·Application pending·0 cites
- 3255US2023158165A1Tregitope constructs useful in the prevention and treatment of type 1 diabetesEPIVAX INC·Filed 2021·Application pending·0 cites
- 3354US10286063B2Modified H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequenceEPIVAX INC·Filed 2016·Granted May 14, 2019·0 cites·11 claims
- 3453US2023192777A1Epitopic vaccine for african swine fever virusEPIVAX INC·Filed 2020·Application pending·0 cites
- 3549US2023127506A1Modified interferon-alpha-2 having reduced immunogenicityEPIVAX INC·Filed 2020·Application pending·0 cites
- 3649US2018161420A1Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 SequenceEPIVAX INC·Filed 2018·Application pending·0 cites
- 3737US2018179256A1Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 SequenceEPIVAX INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EPIVAX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →